Evidence Hub

Combined long-acting bronchodilator single therapy for COPD.

Râjnoveanu RM, Antoniu S, Ulmeanu R

Expert opinion on pharmacotherapy, 2014

Abstract

INTRODUCTION: In COPD, the long-acting bronchodilators are not always able to provide an appropriate bronchodilator effect in terms of amplitude and duration and this can result in increased severity of respiratory symptoms and in worsening of health status. Combined long-acting bronchodilators can address this limitation.

AREAS COVERED: Analysis of a recent study evaluating the efficacy and safety of 26 weeks of therapy with glycopyrronium+indacaterol single inhaler (QVA149) versus each component, versus tiotropium and versus placebo.

EXPERT OPINION: Such a combination can provide a superior and sustained bronchodilator effect and can minimize the respiratory symptoms resulting from a suboptimally inhibited bronchoconstriction.

How strong is the evidence?

Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free